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HRQOL outcome measures have been an integral part of EORTC (European Organisation for Research and Treatment of Cancer) clinical trials for the last 30 years. The EORTC created the Quality of Life Group (QL Group) in 1981 with the mission to develop measures of patient-reported outcomes in cancer, including HRQOL, and to promote clinical studies concerning 
the quality of life of cancer patients. In parallel, the EORTC Quality of Life 
Department (QL Department) at the EORTC Headquarters was established to 
provide administrative, practical and scientific support to co-operative groups 
to implement HRQOL measures in their clinical trials.   
 The QL Group has a multi-disciplinary membership with representatives 
from medical and nursing backgrounds, as well as psychologists, statisticians and 
social scientists. Members come from seventeen European countries as well as 
from North and South America, Australia and East Asia. 
 Our scientific programme focuses on three major areas:
1)  Methodological research: to develop and refine questionnaires for assessing 
the HRQOL of cancer patients.
2) Implementation of HRQOL in clinical trials.
3)  Scientific research in patient-reported outcomes: to study the effects of cancer 
and its treatment on the HRQOL of diverse populations cancer patients.
Methodological research 
In the 1990s the EORTC QL Group introduced the concept of modular HRQOL 
measurement in oncology, based on a core cancer questionnaire and cancer site-
specific modules covering specific symptoms, treatment side-effects and functional 
problems. The QL Group was the first to publish detailed guidelines on the 
development of questionnaire modules that have set the standard internationally 
 and have been widely used by researchers and clinicians worldwide. These have 
been regularly updated and are now in their Fourth edition available online.  
 The most notable achievement of the QL Group is the development and 
validation of the core EORTC HRQOL questionnaire, known as the EORTC 
QLQ-C30. The EORTC QLQ-C30 was validated in multiple European 
countries and published in 1993. The EORTC QLQ-C30 represents the most 
widely known example of the influence of the EORTC on international cancer 
research (EORTC QL Group Scientific Advisory Committee review report 2010). 
The EORTC-QLQ-C30 has been one of the most widely used cancer question-
naires in randomised trials in oncology, as demonstrated by systematic reviews. 
User agreements for the EORTC QLQ-C30 have been signed off in more than 
9,000 clinical trials and academic studies worldwide. 
 In addition to the EORTC QLQ-C30, there is a portfolio of supplementary 
questionnaire modules cancer site-specific or symptom/ quality of life domain-
specific. This is an active area of research with ongoing development of 
questionnaires for haematological malignancies, melanoma, doctor-patient 
communication, and updates to existing modules to capture the effects of 
new treatments.  
 A truly unique feature of the EORTC questionnaires is the attention paid 
to cultural and linguistic issues from the beginning of the developmental process. 
All our questionnaires are developed simultaneously in at least three European 
languages. The QL Group is an international leader in developing guidelines 
for translations. All validated questionnaires are available in at least eight key 
European languages. The EORTC QLQ-C30 has been translated and 
linguistically validated into more than 60 languages. 
 The EORTC QL Group created the EORTC Item Bank, a searchable 
database that contains all questions (items) from validated modules with their 
translations. It is a rich resource for developing questionnaires, as it ensures 
compatibility between different EORTC questionnaires, avoids duplicating work 
and makes possible creation of ad-hoc trial/research specific questionnaires. 
Implementation of HRQOL measures in EORTC trials 
HRQOL is an integral part of most EORTC clinical trials, and has been 
systematically implemented over the last 15 years. Over 130 EORTC clinical 
trials have a HRQOL element. There are numerous trials we could mention, but 
we note just two examples below.  
 In patients with glioblastoma, we studied the addition of concomitant and 
adjuvant temozolomide to the standard treatment with radiotherapy, and 
demonstrated that temozolomide significantly improved survival without a 
negative effect on HRQOL. This treatment is now the standard of care in newly 
diagnosed patients with glioblastoma. 
 Dose-intensive chemotherapy had generated much interest in the treatment 
of patients with locally advanced breast cancer as it might offer a survival benefit. 
We compared the effects on HRQOL of dose-intensive with standard chemo-
therapy. Patients assigned the intensified treatment had a significantly lower 
overall HRQOL score during the treatment, but scores returned to near baseline, 
with no difference between groups one year later. This was the first randomised 
trial to show that dose-intensive treatment may lead to a temporary reduction 
of HRQOL, followed by recovery, thus enabling clinicians to give accurate 
information to their patients.
 The QL Department, on behalf of the EORTC Clinical Groups, undertook 
the largest meta-analysis of HRQOL data using the EORTC QLQ-C30 (n=7417 
patients, 11 different cancers from 30 trials). The HRQOL parameters physical 
functioning, pain, and appetite loss, provided significant prognostic information 
in addition to socio-demographic and clinical variables. 
Scientific research in patient-reported outcomes 
The QL Group undertakes successful methodological research in a number 
of key areas.
 Cross-cultural differences between populations in HRQOL assessment. 
Using Item Response Theory and Differential Item Functioning analysis in a 
large database of over 30,000 individuals from 50 countries, we demonstrated 
differences in reporting of pain and social function for Eastern European and 
Asian countries, when compared with the original English version. The reasons 
for Asian countries were primarily cultural, in contrast with Europe, where 
response patterns followed linguistic lines. 
 We are developing a Computer-Adaptive Testing (CAT) Version of QLQ-C30, 
which will allow increased measurement precision and adaptation of the 
questionnaire to the individual study or patient, thus reducing respondent burden. 
 Electronic administration of EORTC QLQ-C30. This project will provide a 
web-based platform for electronic administration of our questionnaires, based 
on a software solution called Computer-based Health Evaluation System (CHES). 
 Summary scores for EORTC QLQ-C30. Further research is being undertaken 
to recommend the generation of EORTC QLQ-C30 summary scores for 
Physical and Mental Health. In clinical trials, summary scores will simplify 
certain analyses and minimize the chance of Type I errors through multiple 
comparisons. 
EORTC Quality of Life Group
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Conclusion
The EORTC QoL Group and QoL Department have been international leaders 
in the development of patient-reported outcome measures in oncology and 
their implementation in oncology trials. Our most notable achievement is the 
development and dissemination of the EORTC QLQ-C30, which is one of the 
most widely used cancer HRQOL instruments. We established internationally 
accepted guidelines for questionnaire development. Our translation procedures 
set the highest standards for questionnaire translation and are used worldwide. 
These world-leading achievements have contributed to bringing HRQOL 
assessment to the fore in many international trials conducted by the EORTC 
and other groups, which have changed oncology practice and brought in patient 
perspective to clinical cancer research. The Group now looks to the future by 
developing ways to use information technology to improve precision of HRQOL 
assessment and accessibility to web-based interface n
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I am grateful to the newsletter editor for inviting me to 
write this piece. 
It made me stop 
and think back 
about what went 
on during the last 
three years.
This was a busy, challenging, but 
ultimately enjoyable time. Leading the 
group was not a hard task, as the group 
was full of energy, enthusiasm and new 
ideas. As a chairperson, I felt my task was 
to support every group member to fulfil 
their potential and encourage them to 
share and shape their ideas. I tried to 
create an atmosphere where every member 
of the group felt valued and welcome to 
join different activities. The chair also 
represents the Group to the EORTC 
Headquarters and Board. In 2010, we 
updated the statutes of the group, to bring 
them into line with the ongoing Group 
changes and the regulatory environment. 
We had a challenging, but positive, 
Scientific Advisory Committee review, 
which resulted in a frank discussion about 
where the group is now, where it is going, and how to address 
the challenges of running quality of life studies outside the 
EORTC data centre.  
 When I took over chairing the group, I mentally set up myself 
several tasks. The first was a conscious effort to improve and enrich 
the collaborative work with the Quality of Life Department. I am 
pleased that we developed the idea of the Data Repository project, 
leading to standardisation of our data collection and data storage 
for all Phase 4 studies. This is a truly joint endeavour, with a close 
working relationship between the Quality of Life Department, the 
Executive committee and the research fellow leading the project. 
 I invested time and effort in supporting discussions about closer 
collaboration with researchers in the United States, particularly in 
the PROMIS project. These conversations are ongoing and, whereas 
we have not got a solution to many of the issues, we now have 
specific plans about small joint projects. Mogens will take over 
this task and we look forward to a fruitful collaboration. 
 I tried to work hard on increasing the engagement of all group 
members and involve them more actively in the management of 
the group. We introduced web based voting for officers of the 
Executive committee, which allows all members to vote in elections. 
I was really pleased that we had several excellent candidates to 
choose from for both the position of chair and of treasurer. I believe 
it is really healthy for any organisation to have people who are 
willing to contribute their time and to work for its success.  
 Finally, as chair, I feel I was blessed with an excellent Executive 
committee. All members contributed enormously to the manage-
ment of the Group, generated ideas, and were engaged in all 
initiatives throughout the three years. I am really grateful for their 
support, hard work and initiative.
Thoughts of the  
Departing Chair of the Group
Galina Velikova 
I wish our new chair,  
Mogens Groenvold to have  
as enjoyable and stimulating  
a time, as I have had. 
My intention is to continue  
to be part of the group  
and undertake new projects  
in the future n
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Greenhouse. Should the ideal university research 
department be a greenhouse where the individual 
researchers have optimal conditions for growing many 
totally different plants? 
 Strategy. Should everybody be working together
on the same, common strategy, thus using all 
resources to grow a single plant species?
 As my university department is typically Danish 
(and Danes are usually consensus-seeking) it has 
never chosen an either/or solution but has instead 
followed a gradual development towards greater 
emphasis on research groups than individualistic 
research.
 When I took over as chair of the EORTC Quality 
of Life Group after having been involved in the 
Group’s work for 22 years I wondered whether the 
same discussion could and should be applied to the 
Group. Had the Group followed the Greenhouse or 
the Strategy approach? And was the Group on the 
right track?
 
 Having watched the development over many 
years, having discussed the Group’s work with the 
Executive Committee and many other members, and 
having read the contributions in this Newsletter 
describing the Group’s past and current activities, 
I think it is evident that the Group (often working 
in collaboration with the QoL Department) is truly 
a Greenhouse: It nurses the growth of many 
entirely different plants. This is one of the things I 
have always particularly liked: a very large number 
of enthusiastic researchers with many different 
backgrounds and ideas who work hard to develop 
a lot of very different research projects and 
implementation activities. They typically use the 
Group as a source of inspiration and for establishing 
international contacts thus transforming local ideas 
into successful, international, collaborative projects.
 However, it is also clear that the Group has 
been consistently working on the single, common 
Strategy developed in the 1980s: the multidimen-
sional, health-related quality of life model using the 
combination of a carefully cross-culturally developed 
core questionnaire and supplementary module 
questionnaires. This common strategy has proven 
extremely useful for obtaining scientifically robust 
insights into cancer patients’ experiences, and still 
forms the basis for all activities in the Group. 
 I do not think this combination of the Greenhouse 
and Strategy approaches needs any adjustment, but 
clearly there are a lot of exciting challenges in the 
years to come. Among other things we will see:
 
•  new and up-dated modules targeted even more 
cancer diagnoses and therapies, 
•  new translations and cross-cultural validation of 
instruments, 
• new important clinical trials,
• web-based administration of questionnaires, 
•  an interactive, computer-adapted version of the 
EORTC QLQ-C30 
•  an even better documentation of all protocols 
and results of the careful development and vali-
dation our questionnaires
 
I really look forward to watching and taking part in 
this work and many other activities in the Group in 
the coming years.
During the more than 2O years I have been working at a university  department we have been discussing 
the same theme every few years:
I will do what I can  
to help keeping the 
conditions for healthy 
growth in the green-
house intact, while  
at the same time  
continuously refining 
and elaborating the 
strategy. In this way 
the Group will  
continue producing 
important new  
knowledge about  
how cancer patients’ 
lives with cancer  
can be improved n
Thoughts from the new chairman 
of the EORTC Quality of Life Group: 
Greenhouse or Strategy?
Mogens Groenvold 
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Advantages of electronic data capture
Electronic patient-reported outcome data capture (ePRO) in daily oncological 
practice or clinical trials allows the convenient measurement of subjective 
physical health status and psychosocial burden with validated measures such as 
the EORTC quality of life (QOL) instruments. Within clinical routine patient-
reported outcomes (PROs) provide additional information for medical decision 
making within individualized cancer treatment. In a research context, PROs 
have become an important outcome measure supplemental to clinical parameters 
such as survival and time to tumour progression.
 ePRO will help to further increase the use of PRO measures within clinical 
trials and daily clinical practice. In a trial setting ePRO reduces data collection 
costs and increases data quality, since patients enter data directly into a database 
themselves which also reduces data entry errors. Also, the problem of a high 
percentages of missing PRO data in studies may be partially overcome, as a 
central database allows providing information on missing PROs at certain centers 
or in specific patient groups at any time. Within paper-pencil data collection 
analysis of missing data can only be done at various intervals, thereby not allow-
ing immediate response to study logistic problems. In addition, ePRO can include 
automatic e-mail or SMS reminders to patients or study nurses in the case of 
omitted assessments. An important requirement for software packages used in 
clinical trials is compliance with the Good Clinical Practice (GCP) guidelines. 
These require for example a protocol system tracking data entry and any changes 
to the database.
 A persuading method for ePRO is data collection via a web-interface which 
guarantees simple implementation of ePRO logistics, e.g. in hospitals participating 
in international multi-centre studies. Instead of potentially laborious, local 
implementation of ePRO software, a computer with web-access is sufficient to 
administer questionnaires. 
 With regard to daily clinical practice the relevance of ePRO may be even 
higher, since ePRO is necessary not only for reduction of resources required for 
data collection, but also for intuitive, graphical presentation of PRO results of 
individual patients to the medical staff. 
 
CHES-EORTC
To convey electronic data capture with the EORTC QOL instruments the 
EORTC Quality of Life Group has funded a 2.5-year project to develop an 
EORTC version of the Computer-based Health Evaluation System (CHES-
EORTC). In December 2011 the latest version of CHES-EORTC (4.0) was 
released and made available to the QLG via the CHES website (www.ches.at). 
This release included e.g. a web-interface for questionnaire administration, 
a basic feature for CAT administration, and multilingual questionnaire versions. 
In addition, a web-interface for eCRFs has been developed to be used in inter-
national multi-center studies. Currently, the web-interfaces for the questionnaires 
and the eCRFs are being used in the phase IV study of the testicular cancer 
module. CHES is also planned to be used for ePRO in a trial of the Austrian 
Breast and Colorectal Cancer Study Group (ABSCG) investigating the impact 
of physical exercise on re-currency rates in colorectal cancer patients. To foster 
collaboration within the EORTC there are ongoing discussions with the IT 
section of the EORTC headquarters concerning the possible use of CHES-
EORTC in EORTC trials. In the case of a favourable decision, CHES-EORTC 
would be used alongside the eCRFs provided by the EORTC-owned software 
Vista RDC.
Further ePRO projects
Besides the ongoing CHES-EORTC project several members of the EORTC 
Quality of Life Group are engaged in national projects on ePRO. In the UK, 
Galina Velikova is involved in developing the ePOCS system (Electronic Patient-
reported Outcomes from Cancer Survivors) which links PRO data to existing 
cancer registries. In the Netherlands, Lonneke van de Poll-Franse has set up 
PROFILES (Patient Reported Outcomes Following Initial treatment and Long 
term Evaluation of Survivorship registry). This project has a strong focus on 
psychosocial aspects of cancer survivorship and also includes a large general 
population sample to gain reference scores for interpretation of the results from 
cancer survivors. Also in the Netherlands Irma Verdonck-de Leeuw has developed 
OncoQuest, a touch screen computer system to monitor quality of life of patients 
in clinical practice. Also, she is developing the OncoCompass, a personal e-health 
portal that supports cancer survivors by finding and obtaining optimal 
supportive care, according to stepped care programs and adjusted to their 
personal health status and situation. 
Future developments and challenges
For the future, we expect that electronic PRO data capture will become more 
widespread, which will help to further increase the use of PRO measures in 
clinical studies and daily oncological practice. Within the EORTC Quality 
of Life Group, ePRO via a web-interface will facilitate conduction of module 
development studies. Also, the use of the EORTC CAT measures, which is likely 
to increase within the next years, relies on the availability of ePRO software 
packages. Concerning the use of PROs within daily clinical practice, ePRO 
software packages have helped to overcome a number of logistic barriers. However, 
other challenges still persist, e.g. limited evidence on the benefits of PRO data 
in individual patient treatment, the attitude of the medical staff towards this 
type of subjective information, and the lack of familiarity with PRO scores. This 
emphasizes the need for further research on the impact of ePRO in daily clinical 
practice, for specific training of the medical staff, and for further consolidation 
of PRO research within the oncological field n
Present and future of electronic 
patient-reported outcome data capture  
in clinical trials and daily clinical practice
Bernhard Holzner, Johannes Giesinger, Medical University of Innsbruck, Austria
Web-connected devices 
offer possibilities for  
electronic data capture
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Since the beginning of our research activities some 30 years ago, EORTC Quality of Life Group (QLG) meetings have been attracting many collaborators from throughout Europe and beyond, and the numbers are constantly increasing. Official documentation of the number of attendees started at the Spring meeting in 2001, where 32 colleagues were present. At the following Autumn meeting, there were 43 participants, 
and the numbers have been increasing up to our last meeting, Autumn 2011, 
with 92 attendees (see Fig. 1 for details).
 Currently, the QLG has 83 active members who are actively involved in 
research activities and who are attending at least one meeting within two years. 
Another 112 colleagues are corresponding members who are interested in the 
group’s activities without being able to attend the meetings regularly. Our members 
are from 31 different countries with the UK, Germany, Austria, Italy, and 
The Netherlands the five “top contributors” (see Fig. 2). 
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Different  
Countries
Active  
Members
The EORTC 
QoL Group 
has in
Fig. 1  Number of QLG meeting participants from Spring 
2001 to Autumn 2011. 
Fig. 2 Number of QLG members by country as at Autumn 2011 
83 31
Notes: S = Spring meeting, A = Autumn meeting
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For those of you with a good memory, or who hoard old documents and newsletters you may remember back in Spring 2004 I wrote an article for the QLG Newsletter. The article was written as I came to the end of my term as Honorary Secretary and it reflected on my membership of the group since November 1992. I recounted tales from the 13 cities that I had visited in that time – Brussels, Edinburgh, Trondheim, Warsaw, Pamplona, Besancon, Istanbul, London (my home city), Paris, Oslo, Ulm, Graz & Rome. I mentioned how communication and travel had changed between 1992 and 2004 when internet and e-mails 
were rare, the Channel Tunnel had not been built and cheap flights (unless they included a Saturday 
overnight) were non-existent. So what has changed since 2004 – well most of us now have smart phones 
on which we can read our e-mails and surf the internet almost anywhere. Few of us have to spend time in 
the library searching for paper copies of journals when we can download them onto our PCs. There are 
more high speed trains connecting major European cities but sadly although there are more airline flights 
they never seem to be very convenient and there are longer delays for security and passport checks, so 
international travel still often means hours spent in airports. The impact of all these on our own quality 
of life is debatable!
 In my previous article I also discussed the unique nature of QLG meetings. As a small ‘working’ group 
it is possible to recognise and know almost everyone at each meeting. During the day we work hard in our 
parallel sessions and learn much during the plenary sessions from the expert speakers we are able to invite. 
But in the evenings we have the opportunity to learn about our host city and sample the local food and 
drink. It is during these walks and dinners that some of the most creative ideas originate and are nurtured 
into new cross-cultural research projects. I am sure that in our daily jobs there are some meetings and 
conferences we attend from a sense of duty, aiming to arrive at the last possible moment and leave as soon 
as possible. But I always look forward to QLG meetings – they provide a wonderful opportunity to meet 
with colleagues (some of whom I have now known for almost 20 years) and to find out about European 
history and culture in a way that is often not available as a tourist. I think it is also true to say that QLG 
meetings are almost always met with unseasonably good weather!
 So what are some of the most memorable moments from the last six years as Treasurer? The Tivoli 
Gardens in Copenhagen in Autumn 2005, the 25th Anniversary meeting in Paris in Spring 2006 and a trip 
into the New Forest near Southampton in 2006. A journey to Belfast in 2007 – a city we have probably 
all heard lots about for all the wrong reasons. The docks and harbour area in Stockholm and Liverpool. 
(In Liverpool one of our social events was a visit to the Beatles Museum followed by dinner and entertainment 
from a Beatles ‘tribute’ band – during the interval someone sought me out with the message, ‘Paul McCartney 
is looking for you, he wants to know when he we will get paid!’). Then back to Pamplona and Rome. 
Our two most recent meetings have been in Leipzig and Innsbruck and interspersed with all these were four 
trips to Brussels for EGAM meetings.
 What have I learnt whilst being the Treasurer of the EORTC QLG? There is an English expression, 
“Look after the pennies and the pounds will look after themselves.” Perhaps in our case it should be, 
“Look after the cents and the Euros will look after themselves?” Given all the stories in the newspapers 
about the imminent collapse of the European money market that may not be so easy. During my time as 
treasurer we seem to have defied the common wisdom that everyone is making cuts and our income would 
fall. The increasing recognition of the importance of collecting PRO data has meant that our income has 
increased enabling us to fund more research. And it is in this area that perhaps the role of the Treasurer has 
changed most in the last six years. Clinical and Research Governance has seen a huge increase in the legal 
documentation that is required before a study can commence. It is no longer sufficient for the treasurer 
to be good with numbers and accounts, they also need to be familiar with Good Clinical Practice and the 
regulations around Sponsorship and Funding. I wish Bernhard well as he takes on this responsibility. n
Teresa Young
“Paul McCartney is 
looking for you, he 
wants to know when 
he will get paid!”
Six years as Treasurer...a reflection
Teresa Young, Lynda Jackson Macmillan Centre Mount Vernon Hospital, 
Northwood, Middlesex, UK
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As from January 2012 the EORTC Translation 
Unit has three team members, with Maria 
Arnott, as Translation Officer running most of 
the translation projects, and Dagmara Kuliś, 
Translation Team Leader supervising the overall 
activities, they have been joined by Cheryl 
Whittaker, who will be responsible for contact 
with commercial clients and the administration 
of new translation requests within the framework 
of the new business model. The Translation Unit 
is a truly international team with its members 
hailing from Spain, Poland, and the 
United Kingdom.
 The EORTC Quality of Life Group (QLG) 
has a long tradition in translations of PROs 
and translation methodology research with 
numerous publications, including Translation 
Manuals, papers, conference posters and oral 
presentations. The seminal Translation Manual 
was published in 2002 (ISBN2-930064-28-5). 
 The Translation Unit is extremely interested 
in maintaining an international network 
of language service providers, especially by 
fostering collaboration with three selected 
vendors, namely TransPerfect, Pharmaquest and 
MAPI, as well as with the scientific world. 
With respect to the latter, collaboration with 
the International Society for Quality of Life 
Research (ISOQOL) and its Translation and 
Cultural Adaptation Special Interest Group is 
of major importance. Representatives of the 
QLG and the Translation Unit have attended 
the past three meetings of the TCA-SIG in New 
Orleans (2009), London (2010), and Denver 
(2011). They contribute to the TCA-SIG’s 
scientific agenda, especially with the paper on 
the reconciliation process, and take part in the 
exchange of knowledge and experience during 
the meetings.
The Translation and Cultural Adaptation Special Interest Group (TCA-SIG), established in 2004 during ISOQOL’s annual meeting in Hong Kong, strives to identify and advance research in the fields of translation and cultural adaptation of Patient-Reported Outcomes (PRO) measures.   The TCA-SIG is chaired by Donald Patrick, University of Washington, Seattle, WA, USA, and Katrin Conway, MAPI Research Trust, Lyon, France. The annual focus of the group is decided by the steering committee comprising Donald Patrick, Katrin 
Conway, Mona Martin, Health Research Associates Inc, Seattle, WA, USA and Sonya Eremenco, United 
Biosource Corporation, Bethesda, MD, USA. The TCA-SIG’s 26 members are divided into three subgroups, 
each pursuing individual objectives to meet the overall aim:
1.  The cross-cultural issues subgroup led by Sonya Eremenco addresses issues related to the access of copy-
righted instruments, the translation of PROs and their use in e-format.
2.  The Translation Methodology subgroup is chaired by Mona Martin and pursues a research agenda for 
the development of methodologies in the field of translation and cross-cultural research.
3.  The PRO Translation Certification subgroup coordinated by Mona and Katrin aims at establishing an 
international certification program for PRO translations.  
After conducting exploratory work during the first five years of its existence, the group decided to focus its 
efforts on the publication of findings. The following six topics were identified:
1.  Copyright of translations of PRO measures, rules, and applications. Senior author: Caroline Anfray, 
MAPI Institute, Lyon, France. Submission target: 1st Quarter 2012
2.  Translation of Patient Reported Measures: What type of certification should be offered? Senior author: 
Mona Martin, Health Research Associates, Inc., Seattle, WA. Submission target: 1st Quarter 2012
3.  The process of reconciliation in the translation of quality of life questionnaires: Evaluation of existing 
procedures, criteria and outcomes. Senior author: Michael Koller, Center for Clinical Studies, 
University Hospital, Regensburg, Germany. It will appear in the April 2012 issue of Expert Review of 
Pharmacoeconomics & Outcomes Research 
4.  Efficiency of Translation Methodology in Error-Reduction for new Language Versions of PRO 
Instruments. Senior author: Mona Martin, Health Research Associates, Inc., Seattle, WA. Submission 
target: 2nd Quarter 2012
5.  Translation Difficulties. Senior author: Catherine Acquadro, MAPI Research Trust, Lyon, France. 
Submission target: 2nd Quarter 2012
6.  Pooling cross-cultural PRO data in global clinical trials: How much can a poor measure in a cultural 
subgroup affect the estimation in the overall population? Senior author: Antoine Regnault, MAPI Values, 
Lyon, France. Submission target: 1st Quarter 2012.
The TCA-SIG had its annual meeting during the ISOQOL conference in Denver Colorado on 27 October. 
47 ISOQOL attendees participated in the lively discussion around the two presentations which were the 
highlight of the meeting: 1). “Spanish DTSQ: multiple translations and same language adaptations” by 
Annarita Felici from Health Psychology Research Ltd, University of London, London, UK; 2). “Pilot testing 
translations of PRO measures with populations who are difficult to interview” by Darren Clayson from 
PharmaQuest, Banbury, Oxfordshire UK.
The TCA-SIG’s focus for 2012 will be decided and communicated by the end of the first quarter 2012. 
Please contact Tatiana Gauchon (tgauchon@mapigroup.com) for more information about our group or 
consult the ISOQOL website (www.isoqol.org).  
Special Interest Group (TCA-SIG) 
Translation and  
Cultural Adaptation
Katrin Conway, MAPI Research Trust, Lyon, France
EORTC 
Translation  
Activities  
Dagmara Kuliś, Eva Greimel, Michael Koller
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Principal Investigators
Lonneke van de Poll-Franse, PhD
Eindhoven Cancer Registry/Comprehensive Cancer Center South,  
Eindhoven and Tilburg University, The Netherlands
Fabio Efficace, PhD
Health Outcomes Research
Italian Group for Adult Hematologic Diseases (GIMEMA) Data Center.
Rome.Italy.
Core research team 
Simone Oerlemans
Eindhoven Cancer Registry/Comprehensive Cancer Center South,  
Eindhoven and Tilburg University, The Netherlands
Annarita Cardoni
Italian Group for Adult Hematologic Diseases (GIMEMA) Data Center, 
Rome, Italy
Carien L. Creutzberg, MD, PhD
Leiden University Medical Center (LUMC), Leiden,  
The Netherlands 
Susanne Saussele, MD, PhD
Scientific Network Management, European LeukemiaNet,  
Mannheim, Germany
Prof. Wei Chu Chie   
National Taiwan University, Taipei, Taiwan 
Shirley Crofts, MD
Southampton General Hospital, Southampton,  
United Kingdom
Charalampia Kyriakou, MD
North West London Hospitals National Health Service Trust,  
Middlesex, United Kingdom
Rationale for the development of EORTC  
lymphoproliferative disorders modules
In contrast to the large number of quality of life (QOL) studies in patients with 
solid tumors, relatively few QOL studies have been conducted in patients with 
hematological malignancies, i.e. Chronic Lymphocytic Leukaemia (CLL), Hodgkin 
(HL) and non-Hodgkin lymphomas (NHL)1. The American Society of 
Hematology (ASH) has recently voiced concern about the lack of data in 
this area, advocating urgent efforts to raise the standards of QOL research2. 
International recommendations for various hematologic diseases are paying 
greater attention to QOL issues and are advocating more research into this area2-6.
The treatment of patients with these diseases has witnessed dramatic changes in 
the last two decades and this has resulted in better survival rates. The number of 
trials including QOL outcomes is expected to increase rapidly in this area and 
it is important to include condition-specific QOL questionnaires to describe 
patients QOL in more detail. 
Objective and how many modules to develop?
The primary study objective is to conduct Phases 1, 2 and 3 of module develop-
ment of CLL, HL and NHL to be used in conjunction with the EORTC QLQ-
C30. As differences in age of onset, treatment and prognosis between these 
haematological cancers may influence QOL, an important question was raised 
at the Spring 2011 QLG meeting. Namely, is it possible to develop one module 
covering CLL, HL and NHL issues, or are the QOL issues surrounding these 
diseases sufficiently different to warrant the development of separate modules? 
For example, one could develop modules for indolent NHL and CLL, and one 
for HL and aggressive NHL. This decision will be made only after Phase 1, when 
a sufficient number of health care professionals and patient interviews have been 
conducted. Based on these preliminary interviews a more informed and evidence-
based decision can be taken by the research group. We suggest now that when 
the issues of Phase 1 overlap 50% or more we will develop a haematology mini-
core part, with disease specific sub parts for HL, NHL and CLL. If the issues 
of Phase 1 overlap less than 50% we will develop separate modules. It is also 
possible that HL and NHL issues will be combined in one module and a separate 
module will be developed for CLL. The advantage of this approach is that we 
will efficiently develop what is actually necessary for these three populations.  
Project to date (December 2011)
A systematic review of the literature on the general QOL of HL and NHL 
survivors has been conducted, and has resulted in a publication in Annals of 
Haematology7. The first version of the issue list has been developed and we have 
also used information from two focus group meetings among HL and NHL 
survivors held at the Comprehensive Cancer Centre South in The Netherlands. 
Furthermore, we included previous work, which has been conducted by group 
members that resulted in the EORTC QLQ-CLL16. Centres in five countries 
will participate in Phase 1: Germany Italy, The Netherlands, Taiwan and the 
United Kingdom.
NEW GRANTS
EORTC Quality of Life Group
Development of Measures to assess Quality of Life  
in lymphoproliferative disorders: Chronic Lymphocytic 
Leukemia (CLL), Non-Hodgkin’s Lymphoma (NHL)  
and Hodgkin’s Lymphoma (HL)
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More information or questions?
For additional information or interest in participation in the development of these modules please do not hesitate to contact us. 
You can address your correspondence to: Simone Oerlemans, Eindhoven Cancer Registry, Zernikestraat 29, P.O. Box 231, 5600 AE Eindhoven, The Netherlands;
Email: s.oerlemans@ikz.nl; 
Telephone: +31 40 297 1616; Fax: +31 40 297 1610
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Introduction
Testicular cancer (TC) is characterised by a low prevalence (<1% of all male 
malignancies), a low mortality rate (<5% within 5 years), a young patient 
population (about two thirds <40 years), short hospitalisation, and increasing 
incidence rates1.
 As mortality rates are low most patients diagnosed with TC become cancer 
survivors and then have to cope with cancer survivorship problems, related either 
to the malignancy itself, its treatment or both2. Furthermore the majority of TC 
survivors are men at an age when fatherhood is a very important consideration. 
Therefore, the toxicity of a therapy and the possibility of infertility have to be 
kept in mind3. Because of their age and the high cure-rate, evaluation of long 
term QOL is an important issue in this patient group4. 
 For the assessment of QOL in TC patients the EORTC Quality of Life Group 
has developed the EORTC QLQ-TC26. The QLQ-TC26 module is comprised 
of issues pertaining to symptoms of testicular cancer, treatment-related issues 
and additional dimensions of QOL specific to testicular cancer not sufficiently 
covered by the EORTC QLQ-C30, i.e. treatment side effects, infertility, body 
image and sexuality. The items are applicable to patients under treatment as well 
as to cancer survivors. Phase I-III of the module development process have been 
completed between 2006 and 2011 and the QLQ-TC26 module development 
report has been approved by the EORTC Module Development Committee in 
April 2011.
Objectives
The main aim of this project is to determine the psychometric characteristics 
and the validity of the EORTC QLQ-TC26 in a phase IV field study. 
 Another aim is the evaluation of CHES-EORTC (Computer-based Health 
Evaluation System – EORTC version) with regard to its use for web-based PRO 
data collection and study monitoring in international multi-centre studies. 
As TC patients are a young cancer population, web-based questionnaire 
administration is likely to show high feasibility.
Patient recruitment
The phase IV field study is planned to start in December 2011 and will last until 
November 2014. We plan to recruit 360 TC patients at the participating centers 
and assess them at two time points. Patients will be recruited in Australia, Austria, 
Italy, Spain, Norway, and the UK (see list of collaborators). In addition to these 
centers, we will seek additional collaborators from the newly reconstituted 
EORTC GU Group (we have already contacted them and expect that they will 
be willing to collaborate). 
 The sample should cover the most relevant patients groups in testicular cancer 
patients, that is patients undergoing surgery only, surgery and chemotherapy, 
or surgery and radiotherapy [1, 5]. Given the very high survival rate, a survivor 
group appears to be of special importance, and will also be included. Baseline 
assessment will be done in the hospital (electronically or paper-pencil), whereas 
follow-up assessments will be done either in the hospital or at home on 
the Internet.
Electronic data collection with CHES-EORTC
As noted above the secondary objective is the investigation of the use of CHES-
EORTC for web-based PRO data collection in international multi-centre studies. 
Those centers willing and able (depending on ethical approval and required IT 
infrastructure) to participate in electronic data capture will be provided access 
to the CHES-EORTC data collection website. Our initial discussions with our 
collaborators indicate that at least five centers (Amsterdam, Innsbruck, London, 
Southampton, and Sydney) will be able to use this system. The website provides 
forms for entering clinical and socio-demographic data and allows the patient 
to complete the EORTC QLQ-C30 and the EORTC QLQ-TC26. For questionnaire 
administration, participating centers have to provide patients access to either 
a desktop computer or preferably a tablet-PC with touch screen.
 We will evaluate the use of the electronic version in terms of results from the 
QOL measures, but also seek feedback from users (i.e. collaborators) and patients 
via debriefing forms. At institutions not participating in electronic data capture, 
data will be collected conventionally (follow-up assessments via mail survey).
Conclusion
The EORTC QLQ-TC26 will allow the EORTC QLG to have an additional 
validated measure that will increase the portfolio of tools that the QLG has on 
offer and appeal to future research groups, academics, and industry partners alike.
 Furthermore, as this study includes longitudinal, international, multi-centre 
PRO data collection in a young patient group, we consider it an excellent 
opportunity to investigate benefits, barriers, and requirements of web-based 
electronic PRO data capture with CHES-EORTC. Such knowledge is likely to 
facilitate future PRO data collection within further EORTC studies. Electronic 
PRO data capture may improve questionnaire completion rates, reduce percentage 
of missing items, and reduce costs related to data collection and entry. Therefore, 
we consider such a combined project on module development and electronic 
PRO capture particularly beneficial with regard to further enhancement of the 
EORTC measurement system.
Development of the EORTC 
Testicular cancer module (QLQ-TC26):
a phase IV study including multi-centre electronic PRO data capture with CHES-EORTC
Bernhard Holzner, Johannes Giesinger, Medical University of Innsbruck, Austria
NEW GRANTS
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Current Collaborators:
• Neil Aaronson - Division of Psychosocial Research & Epidemiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
• Juan Arraras - Medical Oncology Department, Hospital of Navarre, Pamplona, Spain
• Andrew Bottomley - EORTC Headquarters Quality of Life Department, Brussels, Belgium
• Fabio Efficace - Health Outcomes Research Unit, Italian Group for Adult Hematologic Diseases (GIMEMA) Data Center, Rome, Italy
• Marianne Hjermstad - The Cancer Center, Oslo University Hospital, Ullevål, Norway
• Colin Johnson - University Surgical Unit, Southampton University Hospitals, Southampton, UK
• Madeleine King - Psycho-Oncology Co-operative Research Group, School of Psychology, University of Sydney, Sydney, Australia
• Hannes Steiner – Department of Urology, Innsbruck Medical University, Innsbruck, Austria
• Teresa Young - Lynda Jackson Macmillan Centre, Northwood, UK
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What is this  
PROMOTION Project about? 
Randomized controlled trials (RCTs), play a key role 
in cancer research as they provide the scientific 
evidence needed to adopt the best treatment for all 
cancer patients. The provision of quality care depends 
on the ability to make choices from robust scientific 
data. Health-related Quality of Life (HRQOL) and 
other types of Patient Reported Outcomes (PROs) 
are now a standard component in various trials. 
Including HRQOL as an endpoint in a RCT setting 
could provide invaluable information related to func-
tional ability as well as treatment side effects from 
the patients’ perspective. However, assessing HRQOL 
requires making a number of challenging decisions 
with regard to, for example, data collection, appropri-
ate timing of assessment, adequate statistical analysis 
as well as outcome interpretation. Inadequate or 
poorly designed and reported HRQOL investigations 
in the context of RCTs can mislead clinical decision 
making, as it hampers a clear appraisal of the 
validity of the outcomes. Cancer patients require 
information not only related to survival estimates, 
but also regarding HRQOL issues. Therefore providing 
patients with such information, from a 
methodologically sound research basis, is of 
paramount importance.
 Some ten years ago an editorial published in 
Journal of Clinical Oncology by Mark N. Levine and 
Patricia Ganz, entitled “Beyond the development of 
quality of life instruments: where do we go from 
here?” raised an important issue in this area of 
research. The authors stated that it is “disappointing” 
that, despite the fact that thousands of patients have 
been enrolled in cancer clinical trials with a HRQOL 
component, “there are relatively few examples 
of formal quality of life measurement that have 
influenced individual patient decision-making or 
treatment policies”. Is this still entirely true after 10 
years of research in this area?
What are  
the Objectives? 
The broad scope of the EORTC QLG PROMOTION 
Project is to investigate the quality of HRQOL/PRO 
reporting in oncology RCTs to establish whether this 
has improved over time. This is a large project and 
we expect several publications out of this work, 
so we are happy to have the contributions of additional 
EORTC QLG members. Please, do not hesitate 
to contact us for additional Information. We will 
investigate the consistency of patterns of reporting 
of HRQOL/PRO over time to help answer the 
following question: what are we still missing to bridge 
the gap between HRQOL/PRO research and clinical 
practice applications? 
Some of  the main goals:
1)  To investigate whether there has been a learning 
curve in terms of the quality of HRQOL-PRO 
assessment in RCT reports. Such evaluation will 
be performed separately for each cancer disease 
site where the EORTC QLG has modules 
(i.e. solid tumours and hematologic malignancies) 
2)  To investigate the robustness (in terms of 
psychometric properties) of HRQOL/PRO 
instruments used in these trials and evaluate the 
proportion of those that have used the EORTC 
QLG measures. This will be performed according 
to recently published standard criteria.
How we will  
reach this goal? 
There will be three main steps.
1)  Collecting evidence-based data. Systematic 
literature searches on all cancer RCTs will be 
performed. Any RCT including HRQOL as 
an endpoint (either primary or secondary) will 
be considered.
2)   Data extraction. Each RCT will be evaluated 
on a number of criteria including study design, 
study sponsorship, and methodological issues 
(including the forthcoming CONSORT 
HRQOL/PRO criteria). A large electronic 
database will be developed for the purpose 
of this research to store data collected from 
literature reviews. 
3)  Data analyses and manuscript writing. 
Statistical analyses will be performed to investigate 
reported quality trends over time. Several 
manuscripts are envisaged from this project, 
including a series of systematic reviews. All 
publications will be on behalf of the EORTC 
QLG Promotion project.
Patient Reported Outcome Measurements
Over Time In ONcology (PROMOTION) Project.
Investigating the evolution of reporting quality of life/patient-reported outcomes  
over time in cancer clinical trials and the use of EORTC QLG measures.
Fabio Efficace
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The Brain Tumour Group (BTG) of the EORTC has a longstanding reputation in the incorporation of quality of life measurements in their clinical studies. The Brain Module is one of the first developed cancer specific modules1;2 and is, together with the generic EORTC QLQC-30, part of the tools of many completed and still running trials of the group.
 The BTG has been very successful in performing phase 2 and phase 3 
clinical trials during the last decade. Most of the activities of the BTG are focused 
on patients with glioma, primary brain tumours arising from the supporting 
tissue of the brain. Glioma patients eventually inevitably die of their disease. 
Patients with a WHO grade 2 glioma have a median survival of approximately 
six years, whereas the prognosis for patients with WHO grade 3 (or anaplastic) 
glioma and WHO grade 4 (or glioblastoma multiforme; GBM) is even poorer, 
with a median survival of approximately three years and one year, respectively.
 Among the achievements of the BTG are the observations that early 
postoperative radiotherapy of WHO grade 2 glioma patients results in prolonged 
progression-free survival compared with delayed radiotherapy3, that addition of 
concomitant and adjuvant temozolomide chemotherapy to the postoperative 
radiotherapy of GBM patients prolongs survival4, and that the addition 
of chemotherapy to postoperative irradiation prolongs progression-free survival 
of patients with WHO grade 3 oligodendrogliomas and oligoastrocytomas5. We 
are still awaiting the results of, amongst others, a phase 3 trial assessing the effects 
of replacement by, or addition of chemotherapy to the routine postoperative 
radiotherapy in patients with WHO grade 3 gliomas, and a phase 3 trial compar-
ing postoperative chemotherapy and irradiation for WHO grade 2 gliomas. Apart 
from the primary survival endpoints of these trials, translational research 
utilizing both tumour tissue and blood of these patients is coordinated by the 
BTG, and has resulted in improved classification systems of gliomas based on 
molecular markers.
 The efforts of the BTG have thus led to increased survival for many glioma 
patients, but unfortunately, these patients still inevitably die of their disease. 
Awareness of this fact emphasizes the importance of a sound balance between 
treatment and perceived QOL, different from that in cancer patient groups with 
a reasonable percentage of cured patients. This awareness has resulted in the 
implication of QOL measurements in all phase 3 and most phase 2 clinical 
studies of the BTG during recent years6;7. Although many aspects of health-
related QOL are very similar to those of patients with other types of cancer, 
glioma patients are unique due to the impact of cognitive disturbances. Almost 
all glioma patients suffer from cognitive deficits to some extent, and 
these cognitive deficits may hamper adequate reporting of QOL by the 
patients themselves.
A challenge for QOL research in glioma patients in the near future is, therefore, 
to improve assessment of QOL in cognitively disturbed glioma patients. 
We have realised that what clinicians see is not always the same as what patients 
report. A more adequate assessment might be achieved by combining patient-
reported outcomes with information retrieved from proxies of the patient. Whilst 
a handful of published peer-reviewed studies have been conducted using proxy-
reported outcomes, the EORTC thus far has not, in the 140 clinical trials with 
QOL-measurements incorporated, undertaken any work in this area. The added 
value of incorporation of proxy measurements in EORTC BTG studies might 
be many fold: the use of the validated EORTC measures, robust data collection 
procedures, relatively large samples sizes, and, importantly, prospective data 
collection rather than cross-sectional snapshots. For this purpose, QOL proxy-
reported measurements have now been incorporated into two recently started 
BTG studies. As BTG members have all shown an impressive degree of motivation 
in the past for getting good compliance, and QOL papers of our group 
have been published in high impact journals, we are very hopeful that these 
proxy-studies may be a test bed for other groups. Perhaps groups where they 
have patients with advanced cancer and where proxy-reported outcomes may 
also have additional value. We hope that the results of these studies will improve 
our knowledge on the value of proxy-reported measurements and the way they 
should be implemented in future trials n
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The EORTC Brain Tumour Group; 
the value of proxy-reported QOL measurements.
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The 2011 EORTC Symposium held at the European Parliament in Brussels last 7-9 September confirmed the international attention paid to Quality of Life for cancer patients. The event enhanced the previous Symposium by introducing innovations on health related quality of life, symptom research and cancer clinical trials, including their design, implementation and analysis. Thanks to an extraordinary collaboration with the Portuguese Member of the European Parliament Marisa Matias, it was possible to give an institutional framework to the scientific gathering and engage a constructive debate 
with the European legislators and policy makers.
 During the three-day event 31 Faculty, international leaders in their fields, presented diverse perspectives 
on HRQOL. All the different stakeholders in clinical research were involved including European patient 
groups. Patricia Garcia-Prieto and Šarūnas Narbutas from the ECPC (European Cancer Patient Coalition), 
Jan Geissler from CML Advocates network and Louis Denis from Europa Uomo gave an insight into 
the patient experience, addressing difficulties such as access to international clinical trials, survivorship 
issues etc.
 The figures fully confirmed the success of the event, with 240 attendees from 44 different countries and 
the positive feedback from the participants wishing to repeat the experience. Andrew Bottomley, Head of 
the QOL Department and Symposium Chair, announced a 2012 Conference (17-19 October) co-funded 
by a European Commission grant with the aim to give continuity to this initiative.
 In order to facilitate the participation of young investigators and those from developing countries the 
EORTC created a Travel Fellowship program. Hundreds of applications were submitted, and the QOL 
Scientific Committee selected with scrupulous care the 30 awarded from many worthwhile candidates with 
promising CVs. The awarded Fellows represented 23 countries, bringing a particular and fresh view. We 
asked the Fellows to talk about their Symposium experience and here are accounts of young investigators 
from Poland, Portugal, Malaysia, Egypt and China describing not only the scientific value but also the 
networking opportunities the Symposium represented for them.
              
Rossella Guzzo Foliaro
I am a 26 year old medical doctor from  
Poland. I am currently in my internship  
year and working at the J. Dietl Specialistic  
Hospital in Krakow, Poland. As for next years’ 
plans I am going to start my PhD studies at 
the Jagiellonian University in Krakow and 
continue my work as a physician.
 My scientific interests focus mainly  
on health-related quality of life and overall 
physical and mental well-being of patients. 
As a medical doctor I am trying to popularize 
the concept that though fighting to cure  
patients is of great importance, doctors  
cannot forget that for some patients good 
quality of life is more important than  
prolonging life “no matter the cost”.
 Currently I am involved in a series of 
projects focused on translating and validating 
the EORTC’s tools for health-related quality 
of life assessment in cancer patients. Even 
though most of EORTC’s tools have been 
translated into Polish, not all of them have 
been psychometrically validated. So there  
is still lot of work ahead.
 Quality of life concepts are quite popular 
in my country and many researchers work  
in that field. Quality of life starts to be seen  
as a possible outcome measure in  
clinical trials in Poland, thus the need  
for appropriate instruments. That is why  
we are currently working on translating  
and validating the EORTC tools.
 Taking part in the 2nd EORTC Symposium 
 on Quality of Life, Symptom Research 
and Patient Reported Outcomes in Cancer 
Clinical Trials was a great experience for 
me. It gave me the chance to meet people 
from all over the world and exchange ideas 
about working on and with patients reported 
outcome measure. It has beyond doubt 
proven to me that the quality of life concept 
is popular all over the world. Things that I 
have learned at the Symposium will certainly 
contribute to my future work, especially the 
Translation Workshop and the talk by Prof. 
Eva Greimel about designing quality of life 
questionnaires.
 Once again I would like to say that 
attending the Symposium was a fantastic 
experience. It was great to meet the EORTC 
staff in person.
Krzysztof Tomaszewski
Jagiellonian University Krakow, Poland
2nd EORTC Symposium: 
Quality of Life, Symptom Research  
and Patient-Reported Outcomes  
in Cancer Clinical Trials 
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When I was at the preliminary stage  
of planning my current research on the  
outcome of tumour-related hemipelvectomy,  
a colleague suggested including Quality  
of Life (QOL) assessment into it. It was  
something new to me, but from there on,  
I came across with the EORTC QOL-30  
Questionnaire, and was invited to attend  
the symposium in Brussels. It was an  
amazing experience! The lectures were  
inspiring, some of the speakers made the 
whole idea on QOL research sound very  
interesting and meaningful. 
 I can still remember my short discussion 
with Corneel Coens during one of the breaks.  
I would like to specially thank him for his  
willingness to spend time to discuss and  
giving his sincere and motivating suggestions 
on my research. Back in Malaysia, the last  
decade had seen a boom in health related 
quality of life (HRQOL) research. This may  
be related to researchers’ readiness to  
use the generic HRQOL by World Health  
Organization (WHO). With the increasing 
improvement in the management of  
incurable or chronic illnesses, HRQOL  
is gradually incorporated to assess the  
quality of service, cost utility analyses,  
effectiveness of interventions, and the need  
for health care. I am a trainee lecturer and  
a registrar in Orthopaedics, and will be  
completing my Masters by the end of 2012. 
 Capitalizing on my special interest in  
orthopaedic oncology and reconstruction,  
I am seeking as many opportunities as  
possible to gain experience and knowledge  
to improve my services and management  
to orthopaedic cancer patients. I would like  
to thank the EORTC for awarding me the  
Travelling Fellowship and looking forward  
to share the result of my research once  
completed. 
Mohd Ariff Sharifudin 
Department of Orthopaedics, Traumatology  
and Rehabilitation, Kulliyyah of Medicine
International Islamic University, Malaysia
I’m a 30-year-old Portuguese Medical  
Oncology resident, at the verge of becoming 
a specialist. Health-related Quality of Life 
(HRQOL) was the motto for the clinical  
research I undertook during my Master  
in Oncology. Presently, I await the public 
defense of the dissertation entitled “Assess-
ing the information given to cancer patients 
attending Day Hospital in a comprehensive 
cancer centre”, where I used EORTC QLQ-
C30 and its information module EORTC 
QLQ-INFO25 as measurement instruments. 
 Attending the EORTC QOL Symposium, 
while writing my dissertation, was fundamental 
 to contact directly with major experts in QOL 
worldwide, learning valuable tips and advice 
from them, and also for the opportunity to 
make contacts with other young researchers 
working in the field, which I believe will  
be most useful to me in the future, as I plan 
to continue working on this subject, namely 
developing a clinical trial where QOL will be 
an important endpoint.
Hi, I am Chloe from China. The 2nd EORTC 
symposium was truly rewarding and  
educational. I benefit a lot from these topics  
of designing, conducting and analyses of  
HRQOL in clinical trials, also gained a lot  
useful information in my own research area  
of gynecological cancer. Those topics in 
genetics and HRQOL were very impressive 
and encouraging. The unique nature of this 
symposium included hearing the voice from 
patient perspective. That’s truly meaningful. 
 From this symposium, I met many top  
researchers and scientists from all over  
the world, the Gala dinner was well organized 
as well!
Ying Chun Zeng 
The Hong Kong Polytechnic University,  
School of Nursing, China
Ana Catarina Pinto
Resident in Medical Oncology
Portuguese Institute of Oncology  
Coimbra, Portugal
I work as an attending physician and  
lecturer at the Department of Clinical  
Oncology, Tanta Faculty of Medicine,  
Egypt. I also spent 2-year fellowship at the 
Department of Oncology, Massachusetts 
General Hospital, Harvard Medical School, 
Boston USA. I have shared in many peer-
reviewed articles and I also edited two 
chapters in the book entitled “Breast Cancer: 
A Multidisciplinary Approach to Diagnosis 
and Management”. 
 The quality of life in patients undergoing 
treatment for cancer is greatly underestimated 
 in Egypt and I think this is one of the major 
defects in our practice. I learned about the 
EORTC symposium from the website and 
I was so happy to know about the travel 
awards. I applied and I was lucky enough  
to have the fellowship.
 Attending this meeting was a unique 
experience to me since the topics were 
so much different from any other meet-
ings I used to attend. This has been a very 
powerful life experience for me. The different 
people I met from diverse countries and  
culture has made my learning experience 
more meaningful and real. I’ve seen how 
diversity can result to immense synergies, 
fruitful learning, and strong friendships.  
Also, meeting the experts in this field was  
an excellent chance to exchange thoughts 
with the potential for future collaboration.  
 The EORTC quality of life symposium 
opens me to new perspectives in my career.  
I really enjoyed it very much and I look 
forward to attending future EORTC meetings 
concerning with quality of life in cancer 
patients as far as travel fellowships would 
be granted! 
Mohamed Abd El – Hamid Alm El- Din  
Department of Clinical Oncology 
Tanta Faculty of Medicine, Egypt
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In September 2012 the EORTC QoL group (QLG) for the first time organised a workshop before the regular group meeting. Twenty-five persons attended the workshop on Item Response Theory (IRT) given by statisticians Julie Winstanley and Morten Petersen, both active members of the QLG. Julie started by discussing the fact that most frequently used QoL questionnaires 
often have skewed distributed item or scale scores. 
Interestingly, almost all papers that report on QoL 
outcomes, even from research groups that develop 
these questionnaires, report means and SD’s. This 
is fine if used for descriptive purposes, but not for 
decisions on outcomes. For example to decide 
whether treatment A results in a better QoL than 
treatment B. Furthermore, ordinal scales have the 
typical problem that one cannot assume equal inter-
vals between adjoining points (in contrast to interval 
scaling). For example, the interval between scoring 
2 (‘a little’) or 3 (‘quite a bit’) points on the item ‘Did 
you feel depressed’ might be clinically more important 
than the change between 3 and 4 (‘Very Much’). 
IRT might be of help to overcome the problems 
of parametric testing. The most widely used approach 
for IRT is Rasch analysis. It makes ordinal into 
interval scales by taking the logit for use in parametric 
statistical analyses. Julie interactively took us by the 
hand to do a Rasch analyses of the FACT Melanoma 
surgery subscale, showing that the model fit of this 
subscale improved if a 4-point scale was being applied 
rather than a 5-point scale. 
 In the second half of the workshop, Morten gave 
somewhat more technical details of IRT analyses and 
illustrated this with the EORTC CAT (Computer 
Adaptive Testing) project. CAT is based on IRT, so 
that the response of a previous question is used to 
select the most informative next question. Morton 
also explained the advantages of IRT, (more realistic 
handling of missing data, better and more detailed 
estimation of measurement precision) and challenges 
and limitations of IRT (more complex to understand 
and apply than sum scoring, communicating results 
is more difficult to non-specialists, time consuming, 
larger sample size needed, IRT software not-user 
friendly yet).
 During the workshop the feeling grew that 
questionnaire development should really include IRT 
analyses, at least to overcome all the assumptions 
that are in fact violated by most questionnaires. After 
this workshop I understand the basics of IRT, but 
for now it seems smart to consult an experienced 
statistician when one applies IRT analyses n
Lonneke van de Poll-Franse
EORTC QLG-Workshop: 
Introduction to Item  
Response Theory 
Lonneke van de Poll-Franse, Comprehensive Cancer Center South, Eindhoven
Julie Winstanley Morten Petersen
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A new project to ensure data preservation  
and quality: The Data Repository project
Francesca Martinelli, Quality of Life Specialist, EORTC Quality of Life Department, Brussels
fter writing in March 2011 my first contribution for this newsletter to wave goodbye after 
three years as a research fellow in the Quality of Life Department (QLD), I’m excited to now 
write a new contribution to present an important project: the Data Repository project.
 How was this project born? The Scientific Advisory Committee (SAC) review, 
in 2010, made a number of queries about phase IV of Module Development studies which 
are run outside the EORTC Headquarters. After this review, two main observations were 
made. The first observation was, the Principal Investigator (PI) usually owns the data: 
what happens if the PI leaves the QLG? The second observation concerned the absence of a standard 
protocol template for data collection. The SAC advice was to continue running studies outside the EORTC 
Headquarters, but to create a dataset to store copies of all the data and to develop a standard template for 
data collection for phase IV studies.
 Following the SAC recommendations (endorsed by the EORTC Board and the QLG Executive 
Committee), the Data Repository project was created. I started working on this project in May 2011, under 
the supervision of the Head of the QLD Andrew Bottomley and a committee composed of the former Chair 
of the QLG Galina Velikova and the Chair of Module Development Colin Johnson.
The aims of  the Data Repository project are:
•  to identify and develop generic standards for data collection in order to keep the field  
study process harmonized
• to promote good data preservation strategies
•  to promote the sharing of data for collaborative, high-quality and ethical new research.
This project is important for many reasons. The identification and development of generic standards for data 
collection will harmonize and simplify the field study process. Furthermore, not only will the field study process 
become smoother, but harmonized data will also be an asset in the case of quality control. Data loss will be 
prevented by the creation of a dataset for storage of copies of all the data. Also, last but not least, data sharing 
will permit collaborative, high-quality and ethical new research (subject to defined rules approved by the 
QLG Executive Committee), making good use of the data and enhancing its long-term value.
 In order to identify and develop accurate and complete standards for data collection, it is important to 
conduct a scrupulous review of all existing phase IV protocols. Also, in order to create a central dataset for 
data storage, copies of all data are needed. 
 For these reasons, PIs of phase IV studies conducted outside the EORTC Headquarters have been 
approached. Via a letter presenting the Data Repository project and explaining why we are asking them to 
support this project by providing copies of protocols and data. Contextually, the first draft of a document 
named “Data preservation and sharing initiative” which describes the project, defines rules for data 
preservation and sharing and specifies practical details has been prepared; at the moment of writing 
(December 2011) this document is under final approval by the QLG Executive Committee. The aim of this 
document is to illustrate, regulate and make clear and transparent the whole procedure. This project was 
also presented at the last QLG meeting in Innsbruck in September.
 We are happy to see that PIs are being very collaborative: many protocols and data have already been 
sent, allowing us to start preparing the standard protocol template and to start building the central dataset. 
We are now looking forward to receiving the protocols and data that are still missing in order to be able to 
proceed with this project which is so important for data collection, preservation and quality n
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Chad Gundy, who has died at age 59, was a valued and respected colleague and friend who brought his deep knowl-edge and experience in research methods and statistics to bear on a range of studies in the 
fields of chronic disease, mental disorder and 
oncology. Chad received his bachelor’s degree in 
psychology from the University of Florida, and his 
Master’s degree in psychology, with a focus on 
statistics, methodology and psychometrics, from the 
University of Leiden, the Netherlands. 
 Starting in 1978, Chad worked for some 20 years 
for the Foundation for Scientific Research on Traffic 
Safety, where he did field research, lab studies, and 
scenario and simulation studies, all in the interest of 
making our lives on the highways and byways a little 
bit safer and saner. From 1998 to 2006, he worked 
as a methodologist and statistician in various settings, 
doing survey and marketing research, primary health 
care research, and clinical epidemiological studies. 
In 2006, he joined the Division of Psychosocial 
Research and Epidemiology at the Netherlands 
Cancer Institute in Amsterdam, where he advised on 
and participated in a range of studies on quality of 
life assessment in clinical research and daily clinical 
practice, treatment-induced cognitive deficits, and 
psychosocial issues in cancer genetics
 Chad loved to solve problems; the more 
complicated, the better. With a glint in his eye and 
a devilish grin, he would roll up his sleeves and delve 
into his collection of books, articles, and memory 
cells to come up with not one, but more often than 
not three or four potential solutions. As many of 
those with whom Chad worked were less experienced 
in the mysteries of advanced statistics, he was 
regularly faced with the challenge of explaining his 
ideas and recommendations in a way that everyone, 
from students to high-powered clinicians, could 
understand. He did this with patience, humor, and 
occasionally with the use of colorful metaphors. 
Shortly after joining the Netherlands Cancer 
Institute, Chad became a member of the Quality 
of Life Group of the European Organisation for 
Research and Treatment of Cancer. He participated 
actively in several of the Group’s scientific projects, 
including the Cross-Cultural Analysis Project and 
the QLQ-C30 Higher Order Component Project in 
which he took the lead. Chad continued to work on 
this latter project throughout his time as a patient, 
even preparing a cogent response to extensive peer 
reviewers’ comments and making manuscript 
revisions only weeks before he succumbed to his 
illness. That paper, first authored by Chad, is now 
in press in Quality of Life Research. 
 Given his high level of professional involvement 
and sense of commitment, one might think that it 
was all work and no play with Chad. Nothing could 
be further from the truth. Chad was a true family 
man, devoted to his wife, Mirte, and their two 
daughters, Ellen and Mira. He had a love of classical 
music, was a voracious reader, grew fruit and 
vegetables, and even made wine from grapes grown 
in his own vineyard, no small feat in a damp, cool 
country like the Netherlands. 
 At work, Chad liked nothing more than to 
recommend a biography that he had just read, 
a Mozart concerto that he had heard, or to advise 
on the best way to preserve garden vegetables. It was 
that mix of professional and personal that made Chad 
so very likeable. His appearance reflected that mix. 
His typically “uniform” at work was a blue blazer, a 
pinstriped dress shirt (albeit slightly wrinkled), jeans, 
and a pair of well-worn hiking shoes. From the waist 
up he appeared to be all business, but he was ready 
to take a walk in the woods at the drop of a hat. 
 Chad showed remarkable courage and 
commitment to life – both his working life and his 
family life – throughout the period of his illness. He 
endured the trauma of surgery and the discomforts 
of chemotherapy with dignity, optimism, and even 
humor. He continued to live life to its fullest, within 
the constraints imposed by his physical condition, 
until the very end n
Neil Aaronson, Division of Psychosocial Research 
and Epidemiology, The Netherlands Cancer institute 
and Professor of Clinical Psychology, the University 
of Amsterdam
Neil Aaronson remembers valued colleague and friend 
Chad M. Gundy  
1952 – 2011
“Chad loved 
to solve 
problems; 
the more 
complicated, 
the better.”
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The Autumn meeting 2011 of the Quality of Life Group was, for the first time in EORTC history, held in the very heart of the Alps, in the fifth largest city in Austria, Innsbruck. It was the last meeting before the 50th 
anniversary of the EORTC in March 2012 in 
Brussels. From 14th to 16th of September researchers 
from all over Europe and even Australia were hosted 
by colleagues from Innsbruck, once a central junction 
for cultural and trade routes between northern and 
southern Europe and now “the smallest, yet most 
beautiful world city”, as locals call it.
On the day before the meeting, an opening Workshop 
on Item Response Theory was held. Morten Petersen 
and Julie Winstanley introduced participants, 
statisticians and non-statisticians alike, to different 
methods and concepts of Item Response Theory 
(IRT). Both presented past IRT-experience in testing 
the QLQ-C30 and encouraged people to use IRT 
in developing questionnaires.
 The first day of the meeting started with a 
welcome note from QLG Chair Galina Velikova, 
Corneel Coens from the EORTC Quality of Life 
Department, and from local host Bernhard Holzner. 
Following this introduction, various QLQ-modules 
were discussed in parallel sessions. The Testicular 
Cancer Module, the Elderly Module and the Fatigue 
Module have now completed Phase 3. Other modules 
are currently being updated, for example the Head 
and Neck Cancer Module and the Lung Cancer 
Module. Oral Health and Breast Reconstruction 
Module are currently in phase 3. On Friday, some 
aspiring projects of the Quality of Life Group were 
presented in plenary sessions, the Computer Adaptive 
Testing Project, which has completed three of the 
dimensions of the QLQ-C30, the CHES Project 
which makes the QLGC30 and its modules 
electronically available, and the ongoing intriguing 
work of the Translation Committee. Thirty one new 
translations were finalised in the six months before 
the meeting, e.g. the HDC29 in Japanese, the OG25 
in Farsi, the MY20 in Lithuanian and Hindi. 
EORTC QLG meetings are known and valued 
by attendees not only for their scientific input and 
exchange but also for their social and cultural 
experiences. And this time was no exception 
whatsoever! On Thursday, we enjoyed a breathtaking 
dinner on the ski jump at the Bergisel, introduced 
with a glass of champagne and framed by the sunset. 
From the restaurant on the top of the ski jump, 
a few hundred metres above the city, the organisation 
team of Bernhard Holzner and Johannes Giesinger 
offered free jumps for the bravest of the group. 
Fortunately, no one decided to take on this offer... 
However, invitations from the evening’s music band 
to dance and sing along were wholeheartedly 
embraced. A few of the group members demon-
strated an impressive talent to entertain. The audience 
were swept off their feet. Less wildly celebrated but 
yet highly appreciated was the Friday dinner on Penz 
Hotel’s roof top, one of the best restaurants in town. 
With delicious food and wine, good conversation, 
and much anticipation to our next meeting in 
Brussels we ended our meeting in Innsbruck. A big 
and warm “Thank you” to Bernhard and his team 
not only for organising the meeting and for sharing 
their scientific experience, but also for choosing 
the restaurants and taking us out for after-dinner-
excursions to the nightlife of Innsbruck n
Dirk Hofmeister 
EORTC 
QoL GROUP  
MEETING
Innsbruck, Austria, September 2011
Regensburg, a city with a population of 140.000, is situated in the Free State of Bavaria, Germany, about 100 kilometers northeast of Munich. It is therefore easily accessible via airplane (an airport shuttle can be booked in advance that will take you directly to your hotel) or via Intercity Express trains. Regensburg is an interesting place, economically and scientifically as well as culturally.
 Economically, it is one of the most prosperous regions in Bavaria with world 
class companies such as Siemens, Infineon and BMW as well as numerous suc-
cessful start-up firms in biotechnology. The economic success of Regensburg is 
closely linked to its young university, which was established in the late sixties. 
The University Hospital Regensburg founded 20 years ago is the latest maximum 
care facility of its kind in Germany. Its scientific and clinical focus lies in 
transplantation, immune-oncology and functional genomics.
 Historically, Regensburg looks back to a 2000-year old tradition. Located 
on the river Danube and unharmed by the Second World War, Regensburg 
is regarded as one of Germany‘s most beautiful mediaeval cities. In recognition 
of its former political importance, its role as a mediaeval trading centre and 
the quality of its architecture, Regensburg was added to the UNESCO World 
Heritage List in 2006 (quotes taken from www.regenburg.de, this website also 
offers more detailed information). 1200 historic buildings are to be found in the 
city centre around spacious plazas that offer many opportunities to enjoy a cup 
of coffee or a beer outside. Because of this and the large Italian influence in its 
architecture, for example several Patrician towers that add a Mediterranean 
atmosphere to the city, Regensburg is nicknamed “the most Northern City 
of Italy”.
 
Well-known sights include St. Peter’s Cathedral, the Old Stone Bridge and the 
Old Town Hall. The latter was the meeting place of the Perpetual Imperial Diet 
(Immerwährender Reichstag) which may be regarded as a forerunner of the 
European Parliament. Representatives of the Holy Roman Empire, the Estates 
of the realm, the clergy, the nobility and commoners met here to discuss state 
affairs. Famous sayings such as “to put something on the long bench” or “to 
decide something on the green table” have their roots from this political tradition. 
 The location of the congress, the Kolpinghaus (www.kolping-dev.de), is 
located in the city centre so that all famous sites are within walking distance. 
After the conference, you may consider attending the Oktoberfest in Munich, 
which ends on October 7th.
 We are looking forward to welcoming you to Regensburg and trust that you 
will enjoy quality of life both from a scientific and touristic perspective n
Michael Koller
Fall meeting 2012 
of the EORTC QLG 
Regensburg, Germany
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The fall meeting of the  
EORTC QLG will take place  
on October 4th to 5th 2012 
in Regensburg Germany.
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ANNOUNCEMENT
3rd EORTC Conference on QOL and Cancer 
Clinical Trials, 17-19 October 2012, Brussels
The prominence of the Quality of Life field has become recognized as well as the valuable work we have been conducting by a major European Union grant awarded to 
co-fund the 3rd EORTC QOL conference; 
this will take place on the 17-19 October at 
the European Parliament.  
 The conference chair Dr. Bottomley 
stressed that “what’s great about this event is 
having over 30 of the world’s leading QOL 
Faculty attending, from as far afield as 
Australia to Canada and many members of 
the EORTC Quality of Life Group presenting. 
When budgets are tighter in a recession, it becomes 
more difficult to meet and debate in the 
academic setting key issues about conducting good 
quality clinical trials. But for the third year 
running, this conference is free for researchers 
and health professionals to attend”. Additionally 
the EORTC awards 40 Travel Fellowships to 
young investigators and those from developing 
countries, offering financial support of 400 
Euros each to participate to the Conference 
and benefit from their contribution on the 
Design and Implementationof QOL in 
Clinical Trials.  
The European Parliament
 An important role is played by the European Parliament and as 
Dr. Bottomley emphasized “the fact that the European Parliament hosts this meeting 
shows that despite the economic and political challenges that we face, QOL and the 
cancer patients’ needs are still a key concern to our legislators”. Meeting in the
European Parliament provides a special and rare chance for an excellent dialogue 
between researchers and policy. Marisa Matias, MEP who will be co-chairing 
the patient session of the meeting, is the leading supporter of QOL and EORTC. 
Confirming her engagement for cancer patients’ rights, she stated “I am very 
pleased to be hosting for the second time this event and we look forward to seeing 
what advances we have made since we last met. It is critical that the patient’s voice 
is being heard and taken into account in treatment decision making and we hope 
this conference will echo this fact with discussion and debate.”
Further Information
If you are interested in attending it is important to register ASAP, as places are 
limited and on a first come first serve basis. Travel awards should be applied for 
before the 1 May 2012. Please visit www.eortc.be/probe to register and to 
find out more about applying for the Travel Fellowship program. For more 
information please contact qolconference@eortc.be n
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